[Retrospective cohort study of lamivudine therapy in patients with chronic hepatitis B]. / Retrospektive Kohortenstudie zur Lamivudintherapie bei Patienten mit chronischer Hepatitis B.
Dtsch Med Wochenschr
; 126(5): 97-102, 2001 Feb 02.
Article
em De
| MEDLINE
| ID: mdl-11225393
ABSTRACT
BACKGROUND AND AIMS:
Lamivudine, a nucleoside analogue with specific antiviral activity against the hepatitis B virus, is now available as an alternative therapeutic option to standard interferon-alpha treatment in chronic hepatitis B. Larger studies with lamivudine treatment in chronic hepatitis B were mainly performed in North America and Asia. Data on treatment responses in European patients are sparse. Therefore, we evaluated the efficacy and safety of lamivudine therapy in Central European patients and compared the data with the results from international trials. PATIENTS ANDMETHODS:
In this retrospective, multicenter, cohort study, 95 patients with chronic hepatitis B (median age 40.4 years, male 87 patients, female 8 patients, HBeAg positive 47 patients, anti-HBe positive 48 patients), who were treated with lamivudine (100-300 mg/d per os) between 1997 to 1999, were enrolled.RESULTS:
During lamivudine treatment a virologic response with HBeAg to anti-HBe seroconversion was achieved in 22/47 (47%) of the HBeAg positive patients. Pretreatment ALT levels (> threefold the upper limit of normal; p = 0.03) and HBV-DNA serum concentration (< or = 100 pg/ml; p = 0.08) were identified as positive predictors for virologic responses. The virologic response was sustained in six of nine patients who had a follow-up period (median 26 weeks). In anti-HBe positive patients a virologic response with undectable HBV-DNA levels was achieved in 35/48 (73%) patients during lamivudine treatment. Side effects during lamivudine therapy were generally mild and reversible.CONCLUSIONS:
In this retrospective cohort study virologic end-of-treatment responses to lamivudine monotherapy in patients with chronic hepatitis B were comparable with yet reported international trials. Thus, lamivudine represents a cost-effective and well tolerable option in addition to IFN-alpha in the treatment of chronic hepatitis B.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Lamivudina
/
Hepatite B Crônica
Tipo de estudo:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
/
Male
País/Região como assunto:
Europa
Idioma:
De
Revista:
Dtsch Med Wochenschr
Ano de publicação:
2001
Tipo de documento:
Article